AbbVie, Evolus, Medytox Resolve Intellectual-Property Litigation
February 19 2021 - 9:02AM
Dow Jones News
By Dave Sebastian
AbbVie Inc., Evolus Inc. and Medytox said they have settled all
outstanding litigation, including the U.S. International Trade
Commission case, regarding the sale of cosmetic injection Jeuveau
among the companies.
The companies Friday said AbbVie and Medytox will release claims
against Evolus related to the alleged misappropriation of Medytox's
trade secrets. Evolus will also be able to continue commercializing
Jeuveau in the U.S., and similar injection Nuceiva in other
territories where Evolus has licensing rights, they added.
AbbVie and Medytox will get milestone and royalty payments from
Evolus, the companies said.
Medytox's California court case against Evolus will be
dismissed, the companies said.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
February 19, 2021 09:47 ET (14:47 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Apr 2024 to May 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From May 2023 to May 2024